as mentioned in business-standard
Aurobindo Pharma gains on tentative nod for HIV drug
Aurobindo Pharma gains on tentative nod for HIV drug
Aurobindo Pharma gains on tentative nod for HIV drugThe stock up 4% to Rs 842 after the company has received the tentative approval of Dolutegravir 50mg from USFDA for the treatment of HIV.has moved higher by 4.4% to Rs 842 on the BSE after the company announced that it has received tentative approval for 50mg from US Food & Drug Administration (USFDA).The drug is used for the treatment of HIV.
in like manner indiainfoline
Aurobindo Pharma jumps 6.3% after tentative approval for treatment of HIV
Aurobindo Pharma jumps 6.3% after tentative approval for treatment of HIV
Email id *Choose a valid email address - An authentication email will be sent to your email id.Password *Password should have 8 to 12 Alphanumeric Characters with one Special Character.Confirm Password*Password does not match the confirm password.
moreover from thehindubusinessline
Aurobindo gets tentative USFDA nod for HIV drug
Aurobindo gets tentative USFDA nod for HIV drug
PTIAurobindo Pharma has received tentative approval from the USFDA to manufacture and market Dolutegravir, used for the treatment of HIV, in the US market.In a BSE filing, Aurobindo Pharma said it has received "tentative approval for Dolutegravir 50 mg from US Food & Drug Administration (USFDA) for the treatment of HIV."Through an innovative collaboration with ViiV and the Clinton Health Access Initiative, Inc. (CHAI), the product is expected to be launched in sub-Saharan Africa in late 2016."The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product Tivicay of ViiV Healthcare, it added.
No comments:
Post a Comment